# Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

> **NCT03889639** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 130 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** SAR442168
- **DRUG:** Placebo
- **DRUG:** Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)

## Key facts

- **NCT ID:** NCT03889639
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-29
- **Primary completion:** 2020-01-02
- **Final completion:** 2020-01-02
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03889639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03889639, "Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT03889639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*